Tesamorelin dosage: the FDA-approved 2 mg dose vs. the off-label frontier

Unlike most peptides marketed for “optimization,” tesamorelin has a real, written-down dose. It is an FDA-approved drug — sold as Egrifta — and its label defines exactly how much to give, how often, and for whom. That makes the honest answer to “what is the tesamorelin dosage?” unusually clean for one specific use, and unusually empty for the uses that drive most of the searching. This page states the approved dose plainly, sources it, and is then explicit that the off-label “anti-aging,” bodybuilding and fat-loss applications have no established dose at all.

The approved dose: 2 mg subcutaneously, once daily

Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH). Its single FDA-approved indication is the reduction of excess abdominal fat (visceral adipose tissue) in adults living with HIV-associated lipodystrophy. For that indication, the prescribing information specifies a fixed, non-weight-based dose: 2 mg injected subcutaneously once daily, rotated into the abdomen, reconstituted from the supplied vial just before use.^[1] This is not a range to be titrated or a number copied from a forum — it is the dose that was studied, approved, and labeled.

That 2 mg figure is anchored to actual trial data, not convention. In a randomized, double-blind, placebo-controlled trial in patients with HIV and excess abdominal fat, daily 2 mg tesamorelin significantly reduced visceral adipose tissue versus placebo over 26 weeks while raising IGF-1, the downstream marker of growth-hormone activity.^[2] A pooled analysis of two phase 3 trials, with safety-extension data, confirmed the same daily 2 mg dose reduced visceral fat and characterized its safety profile across roughly a year of use.^[3] So when a clinician prescribes tesamorelin, the dose, the schedule and the endpoint it was meant to move are all documented in the same place.

What the label dose does not cover

Everything outside HIV-associated lipodystrophy is outside the label. The approved 2 mg daily dose was validated for reducing visceral fat in one patient population with one measurable endpoint. It was not established as a dose for healthy adults seeking general fat loss, “GH optimization,” better sleep, muscle gain, or slowing aging. The drug raises IGF-1 reliably — that much is consistent across the trials — but moving a hormone marker is not the same as delivering the body-composition or longevity benefits these off-label uses are sold on. We walk through what the human data do and do not show in our tesamorelin (Egrifta) evidence review.

This is the crucial distinction: a number in a drug label is a different kind of object than a number on a compounding-pharmacy instruction sheet or a research-vendor protocol. The first was earned through controlled trials tied to a defined indication; the second is a convention with no approval and, for these uses, no randomized outcome evidence behind the specific dose being suggested.

The off-label supply problem sits on top of the dosing gap

There is a second reason this page is not a how-to for non-approved use. Off-label tesamorelin reaches people mainly through compounding pharmacies and “research-use-only” channels, and in those channels the concentration, purity and identity of what is in the vial are not guaranteed to the standards of an approved drug product. A dose is only meaningful if you actually know how much active, correctly synthesized peptide you are administering. Pairing an unvalidated off-label dose with an unverified product compounds the uncertainty rather than resolving it — and tesamorelin can affect glucose tolerance and IGF-1, so guessing on both the dose and the source is not a small risk. The same framing applies across this class; see the clinical-vs-modern split in our sermorelin dosage explainer.

The honest bottom line

Tesamorelin genuinely has a dose: 2 mg subcutaneously, once daily, FDA-approved and trial-anchored for adults with HIV-associated lipodystrophy. That is a real, citable number tied to a real indication and a measured outcome. The off-label “anti-aging,” bodybuilding and general fat-loss uses that dominate search interest have no comparable foundation — no approval for those purposes, no randomized outcome trials validating a dose, and no guarantee of what is in a non-pharmaceutical vial. Stating the approved dose is fair; presenting any off-label protocol as evidence-based would not be. If you are weighing tesamorelin, the appropriate next step is a conversation with a qualified clinician about the approved indication — not a dose lifted from a vendor page.